

Document details

1 of 1 → Export → Download More... >

Epilepsia

Volume 60, Issue 9, 1 September 2019, Pages 1820-1828

Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis (Article)

Carpio, A., Chang, M., Zhang, H., Romo, M.L., Jaramillo, A., Hauser, W.A., Kelvin, E.A.

View additional authors \checkmark

Save all to author list

View additional affiliations \checkmark

Abstract

Cited by 0 documents

Inform me when this document is cited in Scopus:

Set citation alert >

Set citation feed >

Related documents

Find more related documents in Scopus based on:

Authors > Keywords >

^aSchool of Medicine, University of Cuenca, Cuenca, Ecuador

^bG. H. Sergievsky Center, Columbia University, New York, NY, United States

^cInstitute for Implementation Science in Population Health, City University of New York, New York, NY, United States

^dDepartment of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, New York, NY, United States

^eLi Ka Shing Faculty of Medicine, School of Public Health, University of Hong Kong, Hong Kong fInstitute of Diagnosis by Imaging, Cuenca, Ecuador

Objective: To develop a causal model for the occurrence of neurocysticercosis (NC)-related seizures and test hypotheses generated from the model. Methods: We used data from a randomized controlled trial comparing albendazole with placebo among patients newly diagnosed with NC. Based on our causal model, we explored the associations among albendazole treatment, NC cyst evolution, and seizure outcomes over 24 months of follow-up using generalized linear mixed effect models. Results: We included 153 participants, of whom 51% received albendazole. The association between seizure outcomes and treatment over time demonstrated lack of linearity and heterogeneity, requiring the inclusion of time-treatment interaction terms for valid modeling. Participants in the albendazole group had fewer seizures overall and of partial onset at all time points compared with the placebo group, but the difference increased over the first few months following treatment, then decreased over time. Generalized seizures exhibited a more complex association; those in the albendazole group had fewer seizures compared with those in the placebo group for the first few months after treatment, and then the association reversed and those in the placebo arm had fewer seizures. Adjusting for the number of NC cysts in each phase resulted in an attenuation of the strength of association between albendazole and seizure outcomes, consistent with mediation. Among participants in whom all cysts had disappeared (n = 21), none continued to have seizures. Significance: Albendazole treatment is associated with a possible reduction in focal seizures in the short term (3-6 months), perhaps by hastening the resolution of the cysts. However, the effect is not discernible over the long term, because most cysts either calcify or resolve completely, regardless of whether treated with albendazole. The stage of evolution of the cysticercus is an important consideration in the evaluation of albendazole effect on seizure outcome. Wiley Periodicals, Inc. © 2019 International League Against Epilepsy

SciVal Topic Prominence (1)

Topic: Neurocysticercosis | Cysticercosis | Neurocysticercosis NCC


Prominence percentile: 93.822


Author keywords

 (albendazole)
 (anthelmintic drugs)
 (epilepsy)
 (neurocysticercosis)
 (randomized clinical trial)
 (seizures)

Indexed keywords

EMTREE drug terms: (albendazole) (carbamazepine) (phenytoin) (placebo) (prednisone





Chemicals and CAS Registry Numbers:

albendazole, 54965-21-8; carbamazepine, 298-46-4, 8047-84-5; phenytoin, 57-41-0, 630-93-3; prednisone, 53-03-2

Funding details

Funding sponsor	Funding number	Acronym
	5F31NS051946	
National Institute of Neurological Disorders and Stroke See opportunities by NINDS7	R01-NS39403	NINDS

1

The data used in these analyses were collected for a randomized controlled trial that was supported by the National Institute of Neurological Disorders and Stroke (grant R01-NS39403; W.A.H., principal investigator [PI]). Additional support was provided by the Ruth L. Kirschstein National Research Service Award (grant 5F31NS051946; E.A.K., PI). The analyses presented here were supported by a grant from the Research Institute, University of Cuenca, Ecuador (A.C., PI).

ISSN: 00139580 CODEN: EPILA Source Type: Journal Original language: English DOI: 10.1111/epi.16302 PubMed ID: 31355931 Document Type: Article

Publisher: Blackwell Publishing Inc.

🙎 Carpio, A.; School of Medicine, University of Cuenca, Cuenca, Ecuador;

© Copyright 2019 Elsevier B.V., All rights reserved.

About Scopus

Language

Customer Service

What is Scopus

日本語に切り替える

Help

Contact us

Content coverage

切换到简体中文

切換到繁體中文

Scopus blog Scopus API

Русский язык

Privacy matters

ELSEVIER

Terms and conditions ¬ Privacy policy ¬

Copyright © Elsevier B.V ¬. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

